Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program

By R. Hajjeh, A. Sofair, L. Harrison, G. Lyon, B. Arthington-Skaggs, S. Mirza, M. Phelan, J. Morgan, Wendy Lee-Yang, M. Ciblak and 6 more. Journal of Clinical Microbiology, 2004

701 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/775b2f75e002ded45bc36494716744248513c7a4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. M. Pfaller
2. D. Diekema

In Epidemiology

1. M. Pfaller
2. J. Guinea
3. D. Diekema
4. Emily R. M. Sydnor
5. Trish Perl
6. J. Perfect
7. Arturo Zychlinsky

In Infectious Diseases

1. M. Pfaller
2. J. Guinea
3. D. Diekema
4. V. Brinkmann
5. Emily R. M. Sydnor
6. Trish Perl
7. J. Perfect
8. P. Kubes

Citations in the corpus

• Global trends in the distribution of Candida species causing candidemia. (2014, background): “of candidemia involving the most relevant Candida species from population-based studies conducted in different countries [10,17–26].”
• Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus (2004, background): “The frequency of invasive mycoses due to opportunistic fungal pathogens has increased significantly over the past two decades ( 35 , 74, 83, 88, 89, 101, 106).”
• Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 (2005, background): “For example, the proportion of outpatient candidemia was lower than in the United States (10.8 versus 28% within 24 h of admission), possibly due to a difference in frequency of outpatient CVC use ( 11 ).”
• Epidemiology of Invasive Mycoses in North America (2010, background): “…to this species is associated with a significantly lower mortality rate than are infections due to other common species of Candida (Abi-Said et al. 1997; Almirante et al. 2006; Hajjeh et al. 2004; Horn et al. 2009; Nguyen et al. 1996a; Pappas et al. 2003; San Miguel et al. 2005; Trofa et al. 2008).”
• Hospital Epidemiology and Infection Control in Acute-Care Settings (2011, background): “Identified risk factors for health care-associated invasive candidiasis include the presence of a central venous catheter, prolonged length of hospitalization, broad-spectrum antibiotic use, burns, ICU stay, and parenteral nutrition (118, 152, 351, 353).”
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, background): “(92) have shown that in 1998 through 2000, only 36% of Candida BSIs occurred in the ICU, whereas 28% were community onset in nature, an increase of almost 10% over that reported in 1992 and 1993 (20% community onset) (113).”
• Neutrophil Extracellular Traps Contain Calprotectin, a Cytosolic Protein Complex Involved in Host Defense against Candida albicans (2009, background): “Fungal pathogens, in particular C. albicans , cause an increasing number of severe infections with high mortality rates [18].”
• Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. (2012, background): “However, following the widespread and the increased use of immunosuppressive therapies together with broad-spectrum antibiotic treatment, the frequency of mucosal and systemic infections caused by C. glabrata has increased significantly (Hajjeh et al., 2004).”
• Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “In addition to the changing trends in antifungal susceptibility, there has been a recent shift towards more infections in the immunocompromised host being caused by Candida species other than C. albicans [50, 51].”